348 related articles for article (PubMed ID: 10344751)
21. Modulation of P-glycoprotein transport activity in the mouse blood-brain barrier by rifampin.
Zong J; Pollack GM
J Pharmacol Exp Ther; 2003 Aug; 306(2):556-62. PubMed ID: 12721332
[TBL] [Abstract][Full Text] [Related]
22. Effect of Stemona curtisii root extract on P-glycoprotein and MRP-1 function in multidrug-resistant cancer cells.
Limtrakul P; Siwanon S; Yodkeeree S; Duangrat C
Phytomedicine; 2007 Jun; 14(6):381-9. PubMed ID: 17467965
[TBL] [Abstract][Full Text] [Related]
23. Cepharanthin, a multidrug resistant modifier, is a substrate for P-glycoprotein.
Hirai M; Tanaka K; Shimizu T; Tanigawara Y; Yasuhara M; Hori R; Kakehi Y; Yoshida O; Ueda K; Komano T
J Pharmacol Exp Ther; 1995 Oct; 275(1):73-8. PubMed ID: 7562598
[TBL] [Abstract][Full Text] [Related]
24. Effects of P-glycoprotein modulation on the chemotherapy of xenotransplanted human hepatoblastoma.
Warmann SW; Heitmann H; Teichmann B; Gratz KF; Ruck P; Hunger M; Fuchs J
Pediatr Hematol Oncol; 2005; 22(5):373-86. PubMed ID: 16020127
[TBL] [Abstract][Full Text] [Related]
25. P-glycoprotein restricted transport of nimodipine across blood-brain barrier.
Zhang L; Liu XD; Xie L; Wang GJ
Acta Pharmacol Sin; 2003 Sep; 24(9):903-6. PubMed ID: 12956939
[TBL] [Abstract][Full Text] [Related]
26. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography.
Sasongko L; Link JM; Muzi M; Mankoff DA; Yang X; Collier AC; Shoner SC; Unadkat JD
Clin Pharmacol Ther; 2005 Jun; 77(6):503-14. PubMed ID: 15961982
[TBL] [Abstract][Full Text] [Related]
27. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.
Mistry P; Stewart AJ; Dangerfield W; Okiji S; Liddle C; Bootle D; Plumb JA; Templeton D; Charlton P
Cancer Res; 2001 Jan; 61(2):749-58. PubMed ID: 11212278
[TBL] [Abstract][Full Text] [Related]
28. In vivo reversibility of multidrug resistance by the MDR-modulator dexniguldipine (niguldipine derivative B859-35) and by verapamil.
Dietel M; Boss H; Reymann A; Pest S; Seidel A
J Exp Ther Oncol; 1996 Jan; 1(1):23-9. PubMed ID: 9414385
[TBL] [Abstract][Full Text] [Related]
29. alpha-(3,4-dimethyoxyphenyl)-3,4-dihydro-6,7-dimethoxy-alpha- [(4-methylphenyl)thio]-2(1H)-isoquinolineheptanenitrile (CL 329,753): a novel chemosensitizing agent for P-glycoprotein-mediated resistance with improved biological properties compared with verapamil and cyclosporine A.
Greenberger LM; Collins KI; Annable T; Boni JP; May MK; Lai FM; Kramer R; Citeralla RV; Hallett WA; Powell D
Oncol Res; 1996; 8(5):207-18. PubMed ID: 8884813
[TBL] [Abstract][Full Text] [Related]
30. Iodination increases the activity of verapamil derivatives in reversing PGP multidrug resistance.
Barattin R; Gerby B; Bourges K; Hardy G; Olivares J; Boutonnat J; Arnoult C; D'Hardemare AD; Ronot X
Anticancer Res; 2010 Jul; 30(7):2553-9. PubMed ID: 20682982
[TBL] [Abstract][Full Text] [Related]
31. Molecular targets in oncology: implications of the multidrug resistance gene.
Lum BL; Gosland MP; Kaubisch S; Sikic BI
Pharmacotherapy; 1993; 13(2):88-109. PubMed ID: 8097038
[TBL] [Abstract][Full Text] [Related]
32. Quantitative assessment of P-glycoprotein function in the rat blood-brain barrier by distribution volume of [11C]verapamil measured with PET.
Bart J; Willemsen AT; Groen HJ; van der Graaf WT; Wegman TD; Vaalburg W; de Vries EG; Hendrikse NH
Neuroimage; 2003 Nov; 20(3):1775-82. PubMed ID: 14642487
[TBL] [Abstract][Full Text] [Related]
33. Hypersensitization of multidrug resistant human ovarian carcinoma cells by pluronic P85 block copolymer.
Alakhov VYu ; Moskaleva EYu ; Batrakova EV; Kabanov AV
Bioconjug Chem; 1996; 7(2):209-16. PubMed ID: 8983343
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and evaluation of [11C]XR9576 to assess the function of drug efflux transporters using PET.
Kawamura K; Konno F; Yui J; Yamasaki T; Hatori A; Yanamoto K; Wakizaka H; Takei M; Nengaki N; Fukumura T; Zhang MR
Ann Nucl Med; 2010 Jun; 24(5):403-12. PubMed ID: 20361276
[TBL] [Abstract][Full Text] [Related]
35. Dynamics of multidrug resistance: P-glycoprotein analyses with positron emission tomography.
Hendrikse NH; Vaalburg W
Methods; 2002 Jul; 27(3):228-33. PubMed ID: 12183111
[TBL] [Abstract][Full Text] [Related]
36. P-glycoprotein and pharmacokinetics.
Levêque D; Jehl F
Anticancer Res; 1995; 15(2):331-6. PubMed ID: 7763002
[TBL] [Abstract][Full Text] [Related]
37. No inhibitory effect on P-glycoprotein function at blood-brain barrier by clinical dose of clarithromycin: a human PET study with [¹¹C]verapamil.
Arakawa R; Ito H; Okumura M; Morimoto T; Seki C; Takahashi H; Takano A; Suhara T
Ann Nucl Med; 2010 Feb; 24(2):83-7. PubMed ID: 20069466
[TBL] [Abstract][Full Text] [Related]
38. p170-dependent multidrug resistance. Restoring full sensitivity to idarubicin with verapamil and cyclosporin A derivatives.
Michieli M; Damiani D; Michelutti A; Melli C; Russo D; Fanin R; Baccarani M
Haematologica; 1994; 79(2):119-26. PubMed ID: 7914881
[TBL] [Abstract][Full Text] [Related]
39. Dual mechanism of daunorubicin-induced cell death in both sensitive and MDR-resistant HL-60 cells.
Côme MG; Skladanowski A; Larsen AK; Laurent G
Br J Cancer; 1999 Mar; 79(7-8):1090-7. PubMed ID: 10098741
[TBL] [Abstract][Full Text] [Related]
40. Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET.
Syvänen S; Blomquist G; Sprycha M; Höglund AU; Roman M; Eriksson O; Hammarlund-Udenaes M; Långström B; Bergström M
Neuroimage; 2006 Sep; 32(3):1134-41. PubMed ID: 16857389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
